Skip to main content

Table 1 Characteristics of clinical trials and patients included in the meta-analysis

From: Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis

Trial name Design Total enrollment number Intervention Control Study quality
James et al., 2017 [7] Open label-phase III 1917 Abiraterone prednisone 5 mg qd ADT ADT alone 4
Fizazi et al., 2017 [13] Double-blind phase III 1199 Abiraterone Prednisone 5 mg qd ADT ADT + placebo 5
Ryan et al., 2015 [9] Double-blind phase III 1088 Abiraterone Prednisone 5 mg bid Placebo Prednisone 5 mg bid 5
Taplin et al., 2014 [14] Open label phase II 56 Abiraterone Prednisone 5 mg qd ADT ADT alone 3
Fizazi et al., 2012 [6] Double-blind phase III 1185 Abiraterone Prednisone 5 mg bid Placebo Prednisone 5 mg bid 5
  1. Abbreviations: ADT Androgen deprivation therapy. qd, once a day; bid, twice a day